In last trading session, 10x Genomics Inc (NASDAQ:TXG) saw 3.16 million shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $9.20 trading at $0.08 or 0.88% at ring of the bell on the day assigns it a market valuation of $1.15B. That closing price of TXG’s stock is at a discount of -198.8% from its 52-week high price of $27.49 and is indicating a premium of 26.3% from its 52-week low price of $6.78.
For 10x Genomics Inc (TXG), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
10x Genomics Inc (NASDAQ:TXG) trade information
Upright in the green during last session for gaining 0.88%, in the last five days TXG remained trading in the green while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $9.20 price level, adding 9.36% to its value on the day. 10x Genomics Inc’s shares saw a change of -35.93% in year-to-date performance and have moved 6.60% in past 5-day. 10x Genomics Inc (NASDAQ:TXG) showed a performance of 12.75% in past 30-days.
Wall Street analysts have assigned a consensus price target of 25 to the stock, which implies a rise of 63.2% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -160.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -160.87% for stock’s current value.
10x Genomics Inc (TXG) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -36.10% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 18.61% while estimates for its earnings growth in next 5 years are of 23.19%.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
FMR LLC is the top institutional holder at TXG for having 13.01 million shares of worth $253.05 million. And as of 2024-06-30, it was holding 10.836 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.19 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4863 of outstanding shares, having a total worth of $198.18 million.
On the other hand, ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025, the former fund manager was holding 8.71 shares of worth $80.14 million or 7.84% of the total outstanding shares. The later fund manager was in possession of 3.24 shares on Apr 30, 2025, making its stake of worth around $29.81 million in the company or a holder of 2.92% of company’s stock.
